Disclosures for "Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Anti-nerve Growth Factor (NGF) Antibody Tanezumab in Subjects with Moderate to Severe Pain Due to Schwannomatosis"
-
Ms. Silverman has nothing to disclose.
-
Jennifer Da has nothing to disclose.
-
The institution of Vanessa Merker has received research support from Children's tumor foundation . The institution of Vanessa Merker has received research support from NF Northeast. Vanessa Merker has received personal compensation in the range of $10,000-$49,999 for serving as a science writer with Neurofibromatosis Network.
-
An immediate family member of Dr. Ly has received personal compensation for serving as an employee of Enanta Pharmaceuticals. Dr. Ly has received research support from Department of Defense. An immediate family member of Dr. Ly has received intellectual property interests from a discovery or technology relating to health care.
-
Alona Muzikansky has nothing to disclose.
-
Dr. Parsons has received publishing royalties from a publication relating to health care.
-
Dr. Wolters has stock in Bristol-Myers-Squibb. The institution of Dr. Wolters has received research support from Neurofibromatosis Therapeutic Acceleration Program.
-
Dr. Xu has nothing to disclose.
-
Dr. Brown has received personal compensation for serving as an employee of Pfizer Inc. Dr. Brown has received stock or an ownership interest from Pfizer Inc.
-
Mr. Haghpassand has received personal compensation for serving as an employee of Pfizer. Mr. Haghpassand has stock in Pfizer. An immediate family member of Mr. Haghpassand has stock in Merck.
-
Dr. Jordan has received personal compensation for serving as an employee of City of Beverly. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Dietitians on Demand. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Genesis HR Solutions. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Harborlight Montesorri. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Navio Theragnostics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Recursion Pharmaceuticals, Inc. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CEC Oncology. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Texas Health Resources. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Children's Tumor Foundation. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BCD Meetings. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shepherd Therapeutics. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Michigan State University. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akeila Bio. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springworks Therapeutics. Dr. Jordan has stock in Navio Theragnostics. Dr. Jordan has stock in The Doctor Lounge. An immediate family member of Dr. Jordan has stock in OldGate. Dr. Jordan has stock in Akeila Bio. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. The institution of Dr. Jordan has received research support from PCORI. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Reimbursement for potential consultant role that was aborted with Magnet Biomedicine. Dr. Jordan has a non-compensated relationship as a board member with United Council for Neurologic Subspecialties that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with Neurofibromatosis Northeast that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with ABA Academy that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a chair, scientific advisory board and board member with Neurofibromatosis Network that is relevant to AAN interests or activities.
-
Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has stock in SonALAsense. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.